Although much is known about magnesium, its interactions with calcium and vitamin D are less well studied. Magnesium intake is low in populations who consume modern processed-food diets. Low magnesium intake is associated with chronic diseases of global concern [e.g., cardiovascular disease (CVD), type 2 diabetes, metabolic syndrome, and skeletal disorders], as is low vitamin D status. No simple, reliable biomarker for whole-body magnesium status is currently available, which makes clinical assessment and interpretation of human magnesium research difficult. Between 1977 and 2012, US calcium intakes increased at a rate 2-2.5 times that of magnesium intakes, resulting in a dietary calcium to magnesium intake ratio of >3.0. Calcium to magnesium ratios <1.7 and >2.8 can be detrimental, and optimal ratios may be ;2.0. Background calcium to magnesium ratios can affect studies of either mineral alone. For example, US studies (background Ca:Mg >3.0) showed benefits of high dietary or supplemental magnesium for CVD, whereas similar Chinese studies (background Ca:Mg <1.7) showed increased risks of CVD. Oral vitamin D is widely recommended in US age-sex groups with low dietary magnesium. Magnesium is a cofactor for vitamin D biosynthesis, transport, and activation; and vitamin D and magnesium studies both showed associations with several of the same chronic diseases. Research on possible magnesium and vitamin D interactions in these human diseases is currently rare. Increasing calcium to magnesium intake ratios, coupled with calcium and vitamin D supplementation coincident with suboptimal magnesium intakes, may have unknown health implications. Interactions of low magnesium status with calcium and vitamin D, especially during supplementation, require further study. Adv Nutr 2016;7:25-43.
Introduction
The role of magnesium in health physiology and metabolism has been well studied; however, its interactions with calcium and vitamin D, especially when magnesium is inadequate, are less well known. This lack of data is in contrast with the extensive literature on interactions of vitamin D with calcium. This article reviews general intakes of and assessment issues for dietary magnesium and explores interactions of magnesium with the nutrients calcium and vitamin D.
Magnesium
Health effects of inadequate magnesium intake Magnesium status is low in populations who consume modern processed-food diets that are high in refined grains, fats, and sugars (1) . Low magnesium status may lead to chronic diseases ( Table 1 ) . For example, studies have linked low magnesium status to a greater risk of metabolic syndrome (MetS) 6 (24, (27) (28) (29) (30) (31) , type 2 diabetes (T2D) (17, 37, 38) , cardiovascular disease (CVD) (7, 8, 39) , skeletal disorders (32, 34, 36, (40) (41) (42) , chronic obstructive pulmonary disease (43) (44) (45) (46) (47) , and possibly some cancers (48) (49) (50) (51) . Low magnesium status has also been associated with depression (52) (53) (54) (55) and decreased cognition (56, 57) . These diseases have large human and financial costs, as reported in the Global Burden of Disease Study (58) . Therefore, there is a need to explore the consequences of suboptimal magnesium status in populations consuming modern processed-food diets. 
Low magnesium dietary intakes in the United States
In a 2011-2012 USDA survey of the latest data available for US dietary intake amounts, mean magnesium intakes for adults were below the RDA ( Figure 1 ) (59, 60). Mean magnesium intakes from food for US adults were comparable to Estimated Average Requirement levels for all adult groups, which is consistent with 50% of the population not achieving adequate dietary magnesium intakes. In specific populations of the 2005-2006 NHANES, the magnesium intake was below the Estimated Average Requirement in diets of 48% of North Americans, 89% of teenaged girls, 55-58% of persons aged 51-70 y, and 70-80% of individuals aged $71 y (61, 62). As a group, adults who use magnesium-containing dietary supplements show a mean magnesium intake above RDA levels ( Figure 1) ; however, their calcium to magnesium dietary intake ratio is also higher, and it is substantially higher in female supplement users in particular (59, (63) (64) (65) (66) (67) (68) (69) (70) (Figure 2 ).
Dietary intake of magnesium has been low for several decades in the United States (72) . In the 1977 USDA nutrient intake survey, the mean magnesium intake from food was 309 mg/d for men (63) . In the 2011-2012 NHANES, the mean magnesium intake had increased by 15.5% (r = 0.78, P = 0.013) to 357 mg/d for men (59) , which was still below the RDA of 420 mg/d. In the same 2 surveys, the mean magnesium intake from foods increased from 216 mg/d in 1977 (64) to 271 mg/d in 2011-2012 for women (59) , which was an increase of 25% (r = 0.93, P < 0.001) but was still below the RDA of 320 mg/d. These increases in magnesium intake over the past 33 y were somewhat Mean bone density 71% of Mg group responded by a 1%-8% increase in bone density, with increases at both 1 and 2 y; mean bone density of all Mg therapy patients increased after 1 y (P , 0.02) and remained unchanged at 2 y (P , 0.05), whereas mean bone density decreased in untreated controls (P , 0.001)
higher but comparable to the increases in food energy between these 2 surveys (i.e., kilocalorie increases of 6% and 17% for men and women, respectively).
Magnesium physiology
In human adults, whole-body magnesium content is ;24 g (1 mol). Approximately half of this magnesium is present in bone and the other half is found in soft tissue, with <1% present in blood. Serum magnesium represents ;0.3% of whole-body magnesium (73) . Although the measurement of serum magnesium is useful in medical diagnoses of clinically severe magnesium deficiency (74), it may not reliably represent whole-body magnesium status. The healthy human body tightly regulates blood magnesium concentrations, maintaining a "normal" range even in times of low dietary magnesium intakes and/or excessive magnesium excretion. Both bone and soft tissue intracellular magnesium concentrations may be depleted (or depleting) while serum/plasma magnesium concentrations remain in the "healthy" range (75) . Pig studies in the 1970s (76) showed that magnesium-deficient pigs had reduced intracellular magnesium from soft tissues and erythrocytes as well as reduced bone magnesium content, although serum magnesium remained at the normal concentration. This magnesium physiology appears to be similar in humans (75) . Thus, in populations who have chronically low dietary magnesium intakes and high dietary calcium to magnesium ratios, such as in the United States (discussed later in this review), people who are nonsymptomatic with normal serum magnesium concentrations may have dangerously low tissue magnesium concentrations and decreasing bone magnesium content. This condition has been termed "chronic latent magnesium deficit" (CLMD) (75) and is further considered later in this review.
Magnesium status assessment
There is currently no simple, reliable biomarker for wholebody magnesium status, and the challenges of assessing magnesium status can impede the interpretation of human magnesium research. The currently available forms of assessment are described below.
Magnesium load retention test as a biomarker. The magnesium retention test is cumbersome but is considered the most reliable research indicator of whole-body magnesium status. In this test, an intramuscular or intravenous infusion of magnesium (the magnesium "load") is given to a subject, followed by urine collection for $24 h. The percentage of the magnesium load excreted in the urine is measured, and the percentage of the magnesium load retained by the body during the length of the urine collection is calculated. Subjects who are magnesium replete are expected to retain small percentages of the magnesium load, whereas subjects with magnesium deficits are expected to show larger retention percentages. Researchers use different retention percentages to define "magnesium deficit" with these load tests (77-81) ( Table 2 ). In addition to its poorly defined cutoffs and its cumbersome nature, the magnesium load retention test cannot be used in patients with chronic kidney disease or in individuals with critical illnesses (82) .
Serum magnesium and CLMD. The largest data source for serum magnesium reference ranges is derived from a 1971-1974 US study in 15,820 presumably healthy individuals aged 1-74 y (83), a population who may not have been fully magnesium replete (75) . Serum magnesium clinical reference ranges in the United States are not evidence based and may include a subpopulation of unknown size with CLMD. The lower serum magnesium range for healthy individuals has been questioned because some studies suggested that the currently accepted lower range correlates with negative health outcomes. The criterion for low "normal" serum magnesium as a definition for hypomagnesemia varies widely in studies ( Magnesium load retention vs. serum magnesium as a biomarker. Data from a small (n = 16) study in Wales reported both individual serum magnesium and magnesium load retention test results for hospitalized patients (77) . The study showed that differentiation between depletion and nondepletion (via the magnesium load retention test) was meaningful only when a serum magnesium value of $0.85 mmol/L was used as the cutoff to define hypomagnesemia (77) . Serum magnesium may not be a reliable marker 4 Healthy serum magnesium reference ranges vary slightly among clinical laboratories and research studies. 5 Proposed cutoff range for a more evidence-based definition of hypomagnesemia (84, FH Nielsen, unpublished data, 2015).
of magnesium status in clinical settings or research studies partly because the accepted "normal range" in North America is not evidence based. For example, individuals in the serum magnesium range from 0.6 or 0.7 up to 0.84 mmol/L are labeled "normomagnesemic" and are thus assumed to be non-magnesium depleted when, in fact, a large portion of these persons might more accurately be designated as magnesium depleted. Well-designed studies comparing results of individual magnesium load retention tests with serum magnesium concentrations are needed to fully explore whether increasing the lower cutoff is warranted.
Value of serum magnesium as a biomarker. Additional research is needed on the proper use of serum magnesium as a biomarker of magnesium status and the possible impact of CLMD. Studies are needed to address whether there are physiologic changes to bone or soft tissue that are associated with low magnesium intakes but normal serum magnesium concentrations. In addition, proton pump inhibitors are widely prescribed and these medications significantly increase the risk of hypomagnesemia in the general population (87) . Recent analysis of human magnesium balance studies suggests that serum magnesium may represent long-term, severely magnesium-deficient status, because it does not respond as rapidly or as flexibly to magnesium intake as does urinary magnesium (FH Nielsen, unpublished data, 2015). At this time, serum magnesium values can be considered a useful, but not an absolutely reliable, indicator of whole-body magnesium status when interpreting human magnesium research.
Urinary magnesium. Urinary magnesium increases with high magnesium diets and/or oral magnesium supplementation and remains low during times of low magnesium intake (88, 89) . A study by Joosten et al. showed that urinary magnesium excretion is an indicator of intestinal magnesium absorption and is thus a potential marker of CVD risk (90) that is perhaps more reliable than serum magnesium (2, 89) .
Calcium

Magnesium interactions with calcium
In humans, it has long been known that hypomagnesemia often presents with hypocalcemia (91) and that calcium intake affects magnesium retention and vice versa (see below). Intricate interactions of magnesium and calcium are basic to all living cells and some are quite early on the evolutionary scale (92) . For example, it was shown in the amoeba almost a century ago (93) that magnesium prevents calcium entry into the cell when calcium is present in excess. In addition, magnesium prevents calcium exit during calcium-deficient conditions and "in the presence of magnesium, less calcium is required for optimum movement" (93) in these one-celled animals. These basic cellular calcium-magnesium interactions are at work in human cells (94, 95) , in which the imbalance of these 2 essential minerals can give rise to cellular phenotypes manifesting the physiologic symptoms of modern chronic diseases (96) .
Change in calcium intake may affect magnesium balance and vice versa Two comprehensive reviews of pre-1970 human studies on the impact of calcium intake on magnesium balance showed that with magnesium intakes <4 mg $ kg 21 $ d
21
, there was magnesium loss regardless of calcium intake; however, when magnesium intakes were $5 mg $ kg 21 $ d
, increases in calcium intake resulted in less magnesium retention (97, 98) . Note that the current adult DRIs for magnesium are based on intakes of 4.3 mg $ kg 21 (100, 101) . In a study in teenaged girls, magnesium balance was negative with calcium intakes of 1800 mg/d; however, compared with positive magnesium balance results with 800 mg calcium/d, the differences in magnesium absorption, excretion, and balance were not significant in this small crossover trial (n = 5) (102). In a randomized clinical trial conducted in New Zealand menopausal women, researchers observed that the consumption of milk high in calcium or supplementation (1200 mg calcium) with or without magnesium significantly increased magnesium urinary excretion during the 8 h of consumption (103) . Another trial in Thai menopausal women found that supplementation with 750 mg calcium for 3 mo led to a 15% increase in urinary excretion of magnesium, but the increase was not significant (104) . A third trial conducted in women aged 24-34 y in The Netherlands found that 400 mg calcium in the form of salts or in cheese increased urinary excretions of magnesium (105) . Although these findings are not entirely consistent and no dietary magnesium intakes were measured, these clinical trials indicate that high calcium supplementation may affect urinary magnesium excretion in women aged $24 y.
With regard to magnesium intakes affecting calcium balance, earlier studies showed that healthy adults with both low magnesium and low calcium intakes had a negative calcium balance, which was attenuated and reversed when magnesium intake improved (97, 98) . More recently, a randomized trial of magnesium supplementation, conducted in Ireland, found that increasing magnesium intake from 11 mmol/d (264 mg/d) to ;22 mmol/d (528 mg/d) for 28 d did not increase urinary excretion of calcium among women aged 20-28 y (106). Another randomized trial conducted in women aged ;40 y in South Africa also found that magnesium supplementation at 250 mg/d (10.3 mmol/d) did not change urinary excretion of calcium, but it reduced fractional absorption of calcium by 23.5%, which was not caused by direct competition between the 2 minerals (107). However, a third trial conducted in men aged 21-42 y in Japan found that supplementation of 250 mg magnesium (as MgO) significantly elevated the urinary excretion of calcium (108) . Note that the Japanese population has a low calcium to magnesium ratio (109) .
High calcium to magnesium ratios in the United States
Over the past $30 y in the United States, both dietary calcium and magnesium intakes have increased. However, calcium intakes increased at a rate 2-2.5 times that of dietary magnesium intakes, giving rise to an increasing calcium to magnesium ratio in this population (Figure 2) . This trend appears to have either reversed or leveled off during 2011-2012, but further surveys are needed to determine which trend, if either, is occurring. Compared with the increases in mean magnesium intakes in US adults (increases of 15.5% and 25% for men and women, respectively; see above) from 1977 to 2011-2012, mean calcium intakes from these same surveys (59, (63) (64) (65) (66) (67) (68) (69) (70) showed increases of 37% in men (from 815 to 1117 mg calcium/d; r = 0.92, P = 0.0005) and 51% in women (from 570 to 862 mg calcium/d; r = 0.95, P = 0.0001). As a result, the mean calcium to magnesium ratio in US adults increased significantly between 1977 and 2012 (for men: r = 0.92, P = 0.0005; for women: r = 0.89, P = 0.001); in 2001, the mean calcium to magnesium ratio increased from <3.0 to >3.0 for both men and women ( Figure 2 ). Increases in mean calcium and magnesium intakes were 3-6 and 1.5-3 times the increases in kilocalories, respectively (17% for women and 6% for men). This high calcium to magnesium ratio appears to be exacerbated by supplement usage, especially in women (110) .
Impact of calcium to magnesium ratios on disease outcomes
Traditional advice is to maintain dietary calcium to magnesium ratios close to 2.0 for optimal health outcomes in humans (111) came from knowledgeable speculation that was not supported by any experimental evidence. In 2007, a colorectal neoplasia study by Dai et al. (71) provided evidence for an optimal dietary calcium to magnesium ratio (i.e., <2.8). In this case-control study (n = 2204), the risk of colorectal adenoma was reduced only in subjects with a calcium to magnesium ratio <2.8, although this risk decreased with increasing total magnesium intakes regardless of confounders. Among those with a calcium to magnesium ratio >2.8, total magnesium intake was not related to risk, although increasing total calcium intake showed a trend toward greater risk. Thus, total calcium intakes may be related to a reduced risk of colorectal adenoma only when calcium to magnesium ratios are <2.8. Dai et al. also found a nutrient-gene interaction [i.e., transient receptor potential melastatin 7 (TRPM7) with dietary Ca:Mg] in relation to the risk of both colorectal adenoma and hyperplastic polyps. TRPM7 is a newly identified gene that is essential to magnesium homeostasis, and the Thr14821le rs8042919 polymorphism in the TRPM7 gene is functional. Individuals with the 14821le allele and calcium to magnesium ratios >2.8 had a 60% greater risk of colorectal adenoma and an 85% increased risk of hyperplastic polyps than those without the 14821le allele in the TRPM7 gene (71) .
A follow-up randomized clinical trial in 930 subjects (112) found that long-term calcium treatment (1200 mg/d over a 4-y period) significantly reduced colorectal adenoma recurrence risk but only when the baseline calcium to magnesium ratio was <2.6 (RR: 0.68; 95% CI: 0.52, 0.90). By contrast, calcium supplementation had no effect among subjects when the calcium to magnesium ratio was >2.6 (RR: 0.98; 95% CI: 0.75, 1.2). This effect modification by the calcium to magnesium ratio cannot solely be attributed to the baseline dietary intake of calcium or magnesium (112) . These results show that the interpretation of studies measuring either calcium or magnesium intake alone is difficult, especially because food sources of calcium and magnesium are positively correlated (113) .
Opposite influence of low calcium to magnesium ratios on health outcomes Just as a calcium to magnesium ratio >2.6-2.8 can result in a detrimental effect, baseline calcium to magnesium ratios <2.0 may also have a detrimental effect. The Shanghai Women's Health Study and the Shanghai Men's Health Study are 2 population-based cohorts with >130,000 participants. These studies were conducted in a Chinese population in whom magnesium intakes are comparable to the US population; however, the median calcium to magnesium ratio (;1.7) is much lower than the calcium to magnesium ratio in the US population ($3.0) (114) . In this population with very low calcium to magnesium ratios, magnesium intakes at or above RDA levels were associated with an increased risk of total mortality in both women and men. This is in contrast with US studies undertaken with a high background calcium to magnesium ratio ($3.0), which showed decreased mortality when magnesium intakes were increased by 200-375 mg/d (7, 13, 115, 116) .
Furthermore, in the Chinese studies, among those with calcium to magnesium ratios >1.7, a magnesium intake $320 mg/d was significantly associated with reduced risks of total mortality and mortality due to ischemic heart disease (IHD) among men and mortality due to all cancers among women. By contrast, when calcium to magnesium ratios were #1.7, magnesium intake $320 mg/d was significantly related to increased risks of all-cause mortality and mortality due to CVD and colorectal cancer among women.
In addition, one study measuring both serum calcium and magnesium found that elevated serum magnesium was significantly associated with a lower risk of high-grade prostate cancer (OR: 0.26; 95% CI: 0.09, 0.85), whereas an elevated serum calcium to magnesium ratio was associated with an increased risk of high-grade prostate cancer (OR: 2.81; 95% CI: 1.24, 6.36) adjusted for serum calcium and magnesium (50) . Another study with an examination of serum concentrations of calcium, magnesium, and phosphorus in a large population of whites and African Americans (27%) indicated that when serum magnesium is low and calcium and phosphorus are higher, this leads to a greater risk of heart failure (117) . With the use of NHANES data, a recent study found that women who met the RDA for both magnesium and calcium had the greatest reduced odds of MetS (OR: 0.59; 95% CI: 0.45, 0.76). In men, meeting the RDA showed no association with MetS, but those with intakes in the highest quartile for magnesium ($386 mg/d) and calcium ($1224 mg/d) had lower odds of MetS (OR: 0.74; 95% CI: 0.59, 0.93) (118) .
In skeletal studies, magnesium depletion was associated with decreased osteoblastic and increased osteoclastic activity (40), lower bone mineral density (BMD) (32, 34, 36) , and fragility. Most studies suggest that magnesium intake favorably alters BMD. In a study by Orchard et al. (33) that used data from the Women's Health Initiative, a lower magnesium intake was associated with lower BMD of the hip and whole body, as expected; however, this did not translate into an increased risk of hip or total fractures. In the same study, excess magnesium appeared to be detrimental to bone and fracture risk of the forearm and wrist. The authors speculated that greater physical activity, made more likely by increased magnesium intakes, was responsible for this unexpected result. It would have been interesting to see whether calcium intakes and calcium to magnesium ratios might have further explained this detrimental outcome of higher magnesium intakes (33) .
Together, these findings suggest that any magnesium or calcium effect is dependent on the intake amount of calcium or magnesium, respectively, and thus on the calcium to magnesium ratio. Furthermore, dietary intake studies of either magnesium or calcium alone may be unwittingly confounded by the unmeasured calcium or magnesium. These findings are relevant to the US population (and other populations experiencing an increased Ca:Mg) because the calcium to magnesium ranges that show these modifying effects (i.e., <1.7 in the Chinese study and >2.6-2.8 in the US studies) are well below the current mean calcium to magnesium ratio in US adults, which was 3.1-3. It appears that too much or too little of either calcium or magnesium might not be beneficial and there may be an optimal range of human calcium and magnesium intake. Studies in this area might expand our knowledge of when supplementation with magnesium or calcium is helpful or detrimental. Long-term exposure to a diet with a high calcium to magnesium ratio, which is common in the United States, may lead to public health concerns and requires further study.
Vitamin D
Magnesium interactions with vitamin D
There has been a recent surge of positive studies for several human health issues with vitamin D in the peer-reviewed literature, giving rise to medical prescriptions for and over-the-counter sales of high doses of vitamin D to increase serum vitamin D concentrations. With early studies showing an effect of magnesium on vitamin D status in patients with clinically diagnosed magnesium deficiency (23, (120) (121) (122) (123) (124) (125) , it is important to review the possible effects of both nutrients on one another in a general population with largely suboptimal magnesium intake (see above).
Vitamin D Status
Vitamin D deficiency causes rickets in children and osteomalacia in adults (126) . Many epidemiologic studies suggest that low vitamin D status may also be associated with allcause mortality (127) (128) (129) and with the risk of nonskeletal chronic diseases such as T2D (130) (131) (132) , CVD (133, 134) , and colorectal cancer (135) (136) (137) . However, findings have not been entirely consistent (138) (139) (140) (141) . Large-scale clinical trials of vitamin D supplementation are ongoing (138, 139, 142) . Despite food fortification and dietary supplementation, low vitamin D status (<20 mg/L or <50 nmol/L; Table  3 ) is still relatively common in the United States (143) . In addition, there is large interindividual variation in serum 25-hydroxyvitamin D [25(OH)D] concentrations that is unexplained by dietary intake of vitamin D and sun exposure alone (144, 145) .
Magnesium is a cofactor in several steps of vitamin D biosynthesis and activation Magnesium, the second most abundant intracellular cation, plays a critical role in the synthesis and metabolism of parathyroid hormone (PTH) and vitamin D (123, 146, 147) . Previous studies showed that the activities of 3 major enzymes that determine 25(OH)D concentrations, 25-hydroxylase, 1a-hydroxylase, and 24-hydroxylase (123, 147, 148) (123) and has been implicated in magnesiumdependent, vitamin D-resistant rickets (146) . In 2 case studies of vitamin D-resistant rickets, magnesium supplementation substantially reversed the resistance to vitamin D treatment (146) , whereas intramuscular infusion of vitamin D as high as 600,000 IU alone did not lead to any improvement in biochemical features of advanced vitamin D deficiency (i.e., serum calcium, magnesium, phosphorus, and alkaline phosphatase; serum vitamin D was not measured) (146) . On the other hand, 2 small clinical studies with no placebo arm conducted in magnesium-deficient patients (123, 149) found that magnesium infusion alone led to a nonsignificant increase in both 25(OH)D and 1,25(OH) 2 D (123), whereas magnesium infusion plus oral vitamin D as 25(OH)D substantially increased both serum 25(OH)D and 1,25(OH) 2 D (149). Thus, these findings showed no effect for a high dose of vitamin D alone or magnesium infusion alone; however, there was a substantial increase in serum 25(OH)D due to vitamin D supplementation with magnesium infusion. Taken together, these findings suggest that a possible interaction between magnesium and vitamin D influences vitamin D status (150) , but these findings should be tested in a large clinical trial.
Effects of interaction between nutritional magnesium status and serum vitamin D on disease outcomes On the basis of this biological plausibility, one recent NHANES study found that a high intake of total, dietary, or supplemental magnesium was independently and significantly associated with reduced risks of both vitamin D deficiency and insufficiency in the general population (150) . In addition, an inverse association between total magnesium intake and vitamin D insufficiency primarily appeared among populations at high risk of vitamin D insufficiency, such as overweight/obese individuals and African Americans. Furthermore, this study also found inverse associations of serum 25(OH)D with mortality (particularly CVD and colorectal cancer) that were modified by high magnesium intake (i.e., the inverse associations were primarily present when the magnesium intake was above the median).
The A previous clinical study found that parenteral magnesium treatment without vitamin D replacement in 23 magnesium-deficient patients led to a normalizing of VDBP. The study also reported a 12% increase in serum 25(OH)D and a 30% increase in serum 1,25(OH) 2 D; however, neither of these changes was significant (123) . In a subsequent study in 5 magnesium-deficient patients, intramuscular treatment with magnesium alone did not significantly increase serum 25(OH)D, but magnesium infusion together with a pharmacologic dose of 25(OH)D substantially increased both serum 25(OH)D and 1,25(OH) 2 D among patients with magnesium deficiency (149) . One interpretation is that magnesium treatment does not affect 25(OH)D status (123, 149) . However, it is also possible that several factors may have contributed to the nonsignificant increase in 25(OH)D status. First, the patients with magnesium deficiency who participated in these previous studies had low concentrations of 25 (147) . Finally, the sample size in these 2 studies may have been too small to show a significant moderate effect of magnesium treatment on vitamin D status.
Similar health effects of vitamin D and magnesium studies Vitamin D and magnesium studies have shown similar associations in several aspects of human health (151) ( Table 1) . In these areas of human disease, vitamin D and magnesium may potentially confound each other or a possible interaction between the 2 may exist. However, almost all studies in these areas measured either vitamin D or magnesium status, not both. This may hamper interpretation of the results. For example, results of studies examining associations between magnesium intake and risk of stroke (6, 152) and IHD (116, 152) have been inconsistent. A meta-analyses of prospective studies found that magnesium intake was related to a significantly reduced risk of stroke; however, this inverse association was weak (an 8% reduction in risk per 100-mg magnesium/d increment) and only 1 of the 7 cohorts included in the meta-analysis found a significant inverse association (6) . Likewise, a prospective cohort study showed that magnesium intake was nonsignificantly inversely associated with IHD, with a pooled RR of 0.86 (95% CI: 0.67, 1.10) for the highest quintile (mean magnesium intake: 433 mg/d) vs. the lowest quintile (mean magnesium intake: 255 mg/d) of intake category (152) . However, it must be noted that 255 mg magnesium/d was found to be adequate for healthy human adults in a series of metabolic unit magnesium balance studies (99) . Similar to these findings in studies on stroke and IHD, several studies evaluated the associations between magnesium intake and the risk of colorectal adenoma and cancer and the results were also not entirely consistent (48, 71, 153, 154) . All of these studies examined associations of disease with magnesium intake only, without considering any interaction with vitamin D. The significant interactions between serum vitamin D and magnesium intakes in relation to mortality due to CVD and colorectal cancer might help to explain such inconsistencies.
Although findings on the potential interaction between vitamin D and magnesium have been promising, only one recent study, to our knowledge, examined the interaction between vitamin D and magnesium in the general population (150). Deng et al. (150) found that magnesium intake may contribute to vitamin D status and that associations between serum vitamin D and mortality risk may be modified by magnesium intake. Because there is currently only one available study, it is difficult to discern whether these 2 micronutrients act independently or synergistically. Future studies are warranted to replicate the findings of Deng et al. and to explore the biochemical basis and molecular mechanisms that would explain these findings.
Areas in need of study on the interaction between magnesium, calcium, and vitamin D Normal vitamin D metabolism requires Mg 2+ for its synthesis and metabolism of parathyroid hormone and vitamin D (see above). The following questions require further exploration: Does low magnesium status affect this activation? Does the calcium to magnesium ratio affect this activation? Does low magnesium status result in low serum 25(OH)D concentrations? Is there an impact of the calcium to magnesium ratio on serum 25(OH)D concentrations? When discerning clinical, biochemical, or physiologic effects of low serum vitamin D, are these effects all or partly due to a low magnesium status or a high calcium to magnesium ratio? Do clinical aspects of magnesium deficit or suboptimal status really derive at least partially from low serum vitamin D associated with low magnesium status or a high calcium to magnesium ratio? Does vitamin D supplementation affect magnesium status in any manner?
Seelig (97, 98) reviewed earlier studies on animals, summarizing that vitamin D supplements improved both calcium and magnesium absorption but also increased magnesium excretion and therefore decreased magnesium retention. In one well-controlled human study (155) , added vitamin D caused a decrease in magnesium retention, as predicted by animal studies. This area requires further study.
Dietary phosphorus interacts with each of the 3 abovedescribed nutrients (magnesium, calcium, and vitamin D) and dietary intakes of phosphorus in US adults are well above the RDA of 700 mg/d. Phosphorus intakes in the United States have remained relatively stable, as have magnesium intakes, compared with the substantial increase in calcium intakes since 1977. Not much is known about the interaction of magnesium with phosphorus; however, because phosphorus is closely linked to calcium, it is possible that phosphorus nutrition affects a population with low magnesium dietary intakes. Indeed, Lutsey et al. (117) found that lower serum magnesium coupled with high serum calcium and phosphorus was a risk factor for heart failure. Interactions of phosphorus with magnesium, calcium, and vitamin D are areas for future study.
Conclusions
The essential micronutrients magnesium, calcium, and vitamin D are each associated with chronic diseases of global concern, including CVD, T2D, MetS, and skeletal disorders. Dietary intakes of magnesium in the US population are low, and dietary calcium intakes in US adults increased 2-2.5 times more than dietary magnesium intakes between 1977 and 2010. Oral vitamin D has recently been recommended and is widely available. Despite these changes in intakes, research on the interactions between these 3 essential nutrients has been sparse.
Measuring magnesium status presents challenges, but magnesium intake is low in populations who consume a modern processed-food diet, including individuals in the United States. High calcium intakes can exacerbate the onset of low magnesium status and vice versa. Studies showed that a calcium to magnesium intake ratio <2.8 is critical for optimal health, supporting a long-held but non-evidence-based recommendation that the calcium to magnesium ratio should be close to 2. Increasing calcium intakes in the United States since 1977 have resulted in a calcium to magnesium ratio >3.0 since 2000, coinciding with increasing rates of T2D and colorectal cancer. US studies assessing oral magnesium therapy or dietary magnesium intakes showed beneficial effects of dietary magnesium in CVD, T2D, and cancers, although similar studies in populations with lower calcium to magnesium ratios ($1.7) reported the opposite, showing the impact that background dietary calcium and/or magnesium can have on studies of either calcium or magnesium alone.
Low vitamin D status is associated with chronic diseases of global concern, as is low magnesium status. Magnesium is a cofactor for vitamin D biosynthesis, transport, and activation. Interactions between magnesium intake and serum vitamin D contributing to the risk of CVD and colorectal cancer were recently indicated. However, epidemiologic data on possible interactions of these 2 micronutrients in human health and disease are very limited. Thus, additional studies are warranted. Increasing calcium to magnesium ratios coupled with oral calcium and vitamin D supplement recommendations in the face of suboptimal magnesium intakes may be affecting health via unstudied impacts of interactions between magnesium, calcium, and vitamin D.
